Vepdegestrant
Science · Tuesday, 7 July 2026
The FDA has approved vepdegestrant, the first therapy based on PROTAC technology.
Quick highlights
- First-in-class PROTAC-based therapy for breast cancer.
- Targets mutated estrogen receptors effectively.
- Offers improved progression-free survival rates.
Context
The FDA has approved vepdegestrant as a novel cancer therapy.
Key Facts
Developed through a partnership between Arvinas, Inc. and Pfizer.
Significance
Addresses resistance in advanced breast cancer treatments.
Challenges / Way Forward
Further research needed to expand PROTAC applications.
Exam Angle
Relevant for GS-III on Health and Technology.
Remember this
- Vepdegestrant is the first PROTAC-based therapy approved.
- Targets ESR1-mutated breast cancer.
- Represents a shift in cancer treatment paradigms.